Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients.

ABSTRACT:

Purpose

To investigate the angiogenic changes in primary tumor tissue of renal cell carcinoma (RCC) patients treated with VEGF-targeted therapy.

Experimental design

Phase II trials of VEGF pathway-targeted therapy given before cytoreductive surgery were carried out with metastatic RCC patients with the primary tumor in situ to investigate the necessity of nephrectomy. Primary tumor tissues were obtained and assessed for angiogenesis parameters. Results were compared with similar analyses on untreated tumors.

Results

Sunitinib or bevacizumab pretreatment resulted in a significant reduction of microvessel density in the primary tumor. Also, an increase in vascular pericyte coverage was found in sunitinib-pretreated tumors, consistent with efficient angiogenesis inhibiti

SUBMITTER: Griffioen AW 

PROVIDER: S-EPMC4015630 | biostudies-literature | 2012 Jul

REPOSITORIES: biostudies-literature